Calendario›REGN›cemiplimab · CLIO-1

cemiplimab · CLIO-1

A Study to Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adult Patients With B-cell Malignancies

Ensayo de REGENERON PHARMACEUTICALS, INC. en Relapsed/Refractory Aggressive B-Cell Lymphoma (del registro, en inglés).

Fase

Fase 1

Estado

Completado

Participantes

105

previstos

Centros

30

Fin del objetivo primario

abr 2026

fecha real

Qué significa cada fase y cada estado.

Estudio de intervención, no aleatorizado, abierto. Comenzó en ene 2016.

Qué mide

Incidence of dose limiting toxicities (DLTs) of cemiplimab in combination with odronextamab (del registro, en inglés) (hasta 28 dias)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThis study is researching a combination of 2 experimental drugs, referred to as "study drugs", called odronextamab (also known as REGN1979) and cemiplimab (also known as REGN2810). The study is focused on patients who have relapse/refractory aggressive B-cell lymphoma. The aim of the study is to see how safe and tolerable the study drugs are, and to define the recommended dose regimen for the combination with odronextamab. This study is also looking at several other research questions, including: * What side effects may happen from taking the study drugs * How effective the study drugs are against the disease * How much study drug is in the blood at different times * Whether the body makes substances or protein called antibodies against the study drugs (that could make the drugs less effective or could lead to side effects)

Más ensayos de REGN

Todos los de REGN, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT02651662), actualizada en jun 2026.